Akt Signaling Accelerates Tumor Recurrence Following Ras Inhibition in the Context of Ink4a/Arf Loss

Gemma L. Robinson, James P. Robinson, Kristin J. Lastwika, Sheri L. Holmen, Matthew W. VanBrocklin

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Aberrant activation of the RAS signaling pathway contributes to nearly all human cancers, including gliomas. To determine the dependence of high-grade gliomas on this signaling pathway, we developed a doxycycline-regulated KRas glioma mouse model. Using this model we previously demonstrated that inhibition of KRas expression in gliomas induced by activated KRas and Akt results in complete tumor regression. We have also shown that, in the context of Ink4a/Arf loss, abrogation of KRas signaling is sufficient to decrease tumor burden but resistance ensues. In this study, we sought to determine the effect of activated Akt signaling in combination with activated KRas and loss of Ink4a/Arf on the growth and recurrence of brain tumors following suppression of KRas expression. We observed significant tumor formation in Ink4a/Arflox/lox mice injected with retroviruses containing tetracycline responsive element (TRE)-KRas, Tet-off, Akt, and Cre. Abrogation of KRas signaling resulted in significant tumor regression; however, resistance developed after a relatively short latency. Tumor recurrence occurred more rapidly and the tumors were more aggressive in the presence of activated Akt signaling compared with loss of Ink4a/Arf alone suggesting that this pathway contributes to tumor progression in this context.

Original languageEnglish (US)
Pages (from-to)476-485
Number of pages10
JournalGenes and Cancer
Issue number11-12
StatePublished - Nov 2013
Externally publishedYes


  • Akt
  • Ink4a/Arf
  • Ras
  • glioma
  • mouse


Dive into the research topics of 'Akt Signaling Accelerates Tumor Recurrence Following Ras Inhibition in the Context of Ink4a/Arf Loss'. Together they form a unique fingerprint.

Cite this